Clinical and laboratory associations of liver fibrosis indexes in patients with decompensated Chronic Heart Failure II-IV Functional Classes

Aim To study clinical and laboratory associations of hepatic fibrosis indexes in patients with decompensated NYHA functional class II-IV chronic heart failure (CHF).
Material and methods The study included 128 patients admitted to the cardiological or therapeutic department of the University Clinical Hospital #4 at the I. M. Sechenov First Moscow State Medical University (Sechenov University) with symptoms of CHF associated with ischemic heart disease (IHD) and/or arterial hypertension (AH). All patients had signs of liver disease (liver enlargement on physical examination ± diffuse changes in hepatic tissue according to ultrasound data). Mean age was 70.59±10.71 years. Along with general clinical examination, severity of hepatic fibrosis was evaluated by calculated indexes, FIB-4, APRI, MELD-XI, and BARD. All calculations were based on laboratory data obtained within the first two days of hospitalization for decompensated CHF, at the onset of active therapy with intravenous diuretics. Statistical analyses were performed with the R programming language (3.6.1).
Results In patients with NYHA FC II–IV CHF, the FIB-4 index significantly increased with the increase in NYHA FC (р<0.05). Also, the high liver density by most fibrosis indexes correlated with the probability of LV EF decrease to <40 % (FIB-4: RR, 1.32 at 95 % CI from 0.53 to 3.28, р=0.079; MELD-XI: RR, 1.62 at 95 % CI from 1.19 to 2.20, р=0.004; BARD: median LV EF, 42.5 % vs. 56 %, р=0.019), and a tendency to heart rhythm disorders was observed (FIB-4: RR, 1.92 at 95 % CI from 0.75 to 4.90, р=0.218; BARD: RR, 1.09 at 95 % CI from 0.97 to 1.22, р=0.174; MELD-XI: RR, 1.34 at 95 % CI from 0.94 to 1.90, р=0.101). Increases in liver fibrosis indexes correlated with other multiorgan disorders in CHF patients evident as a decrease in platelet count (FIB-4: р<0.01; APRI: р=0.045) and a tendency to a decrease in hemoglobin (FIB-4: 127 g/l vs. 137 g/l, p=0.249; APRI: 127 g/l vs. 136 g/l, p=0.749). Patients with a high liver density more frequently had cardiorenal syndrome diagnosed by reduced glomerular filtration rate (GFR) estimated by CKD-EPI to less than 60 ml/min / 1.73 m2 (FIB-4: р<0.03; MELD-XI: p=0.0001; BARD: р=0.005). In comparing liver fibrosis indexes in subgroups of CHF patients with preserved and reduced left ventricular ejection fraction (LV EF), significant differences were found only for MELD-XI (12.08 vs. 9.32, р=0.001).
Conclusions For all studied indexes, correlations were observed with LV EF, decreases in hemoglobin, and incidence of heart rhythm disorders. For the BARD, FIB-4, and MELD-XI indexes, high results of calculations correlated with the presence of other predictors for unfavorable prognosis and disease severity (LV EF, NYHA FC, presence of type 2 diabetes mellitus, chronic kidney disease, and lower GFR). Liver fibrosis indexes are a new and promising but understudied instrument for evaluation of prognosis in CHF patients, which requires further study to determine most appropriate prognostic formulas.

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128

2. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–164. DOI: 10.18087/cardio.2475

3. Poelzl G, Auer J. Cardiohepatic Syndrome. Current Heart Failure Reports. 2015;12(1):68–78. DOI: 10.1007/s11897-014-0238-0

4. Kobalava Zh.D., Villevalde S.V., Solovyeva A.Е. Cardio-hepatic Syndrome in Heart Failure: Prevalence, Pathogenesis and Prognostic Significance. Kardiologiia. 2016;56(12):63–71.

5. Wendon J, Cordoba J, Dhawan A, Larsen FS, Manns M, Nevens F et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. Journal of Hepatology. 2017;66(5):1047–81. DOI: 10.1016/j.jhep.2016.12.003

6. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CSP, Cowie MR et al. Noncardiac Comorbidities in Heart Failure with Reduced Versus Preserved Ejection Fraction. Journal of the American College of Cardiology. 2014;64(21):2281–93. DOI: 10.1016/j.jacc.2014.08.036

7. Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology. 2018;271:132–9. DOI: 10.1016/j.ijcard.2018.04.001

8. Balukova E.V., Uspenskiy Yu.P., Fominykh Yu.A. Liver diseases of various genesis (toxic, drug-induced, dysmetabolic): from etiological heterogenicity to a single unified therapy of patients. Russian Medical Journal. Medical Review. 2018;2(1–1):35–40.

9. Vyalov S.S. Liver route. Outpatient appointments. 2017;3(2(8)):17–24.

10. Pavlov Ch.S. Elastometry or liver biopsy: how to make a correct choice? Russian Medical News. 2008;13(1):31–7.

11. Morozov S.V., Kucheriavyi Yu.A., Stukova N.Yu., Krasniakova E.A. Indirect ultrasound elastography of the liver: from diagnostics of liver fibrosis to control over its treatment. Evidence-based gastroenterology. 2013;2(2):31–7.

12. Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut. 2010;59(7):861–6. DOI: 10.1136/gut.2010.214650

13. Soloveva A.E., Kobalava Zh.D., Villevalde S.V., Bayarsaikhan M., Garmash I.V., Fudim M. Prognostic value of liver stiffness in decompensated heart failure: results of prospective observational transient elastography-based study. Kardiologiia. 2018;17 (S10):20–32. DOI: 10.18087/cardio.2488

14. Allen LA, Felker GM, Pocock S, McMurray JJV, Pfeffer MA, Swedberg K et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. European Journal of Heart Failure. 2009;11(2):170–7. DOI: 10.1093/eurjhf/hfn031

15. Saito Y, Kato M, Nagashima K, Monno K, Aizawa Y, Okumura Y et al. Prognostic Relevance of Liver Stiffness Assessed by Transient Elastography in Patients with Acute Decompensated Heart Failure. Circulation Journal. 2018;82(7):1822–9. DOI: 10.1253/circj.CJ-17-1344

16. Balashova A.A., Arisheva O.S., Garmash I.V., Terebilina N.N., Baronetz V.Yu., Kobalava Zh.D. et al. Diagnosis of liver fibrosis in patients with heart failure. Clinical Pharmacology and Therapy. 2017;26(3):7–12.

17. Vinnitskaya E.V., Keiyan V.A., Sandler Yu.G., Khaimenova T.Yu., Polukhina A.V. Estimation of efficiency of transit fibroelastrometry in non-alcoholic fatty liver disease in patients with obesity. Experimental and Clinical Gastroenterology. 2018;4(152):18–22.

18. Sheptulina A.F., Shirokova E.N., Ivashkin V.T. Noninvasive diagnostic methods of liver fibrosis in patients with primary biliary cirrhosis and primary sclerosing cholangitis: role of indirect serological markers. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(3):52–63.

19. Boursier J, Vergniol J, Guillet A, Hiriart J-B, Lannes A, Le Bail B et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. Journal of Hepatology. 2016;65(3):570–8. DOI: 10.1016/j.jhep.2016.04.023

20. Vyshkovskiy G.L. Register of medicines of Russia radar Doctor: Cardiology and angiology. 18-th ed. – M.: VEDANTA;2014. –720 p. ISBN ISSN 168003124

21. Wai C. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–26. DOI: 10.1053/jhep.2003.50346

22. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57(10):1441–7. DOI: 10.1136/gut.2007.146019

23. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25. DOI: 10.1002/hep.21178

24. Heuman DM, Mihas AA, Habib A, Gilles HS, Stravitz RT, Sanyal AJ et al. MELD-XI: A rational approach to “sickest first” liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transplantation. 2007;13(1):30–7. DOI: 10.1002/lt.20906

25. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin- Venier V et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32–6. DOI: 10.1002/hep.21669

26. Sato Y, Yoshihisa A, Kanno Y, Watanabe S, Yokokawa T, Abe S et al. Liver stiffness assessed by Fibrosis-4 index predicts mortality in patients with heart failure. Open Heart. 2017;4(1):e000598. DOI: 10.1136/openhrt-2017-000598

27. So-Armah KA, Lim JK, Lo Re V, Tate JP, Chang C-CH, Butt AA et al. FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. Hepatology. 2017;66(4):1286–95. DOI: 10.1002/hep.29285

28. Villevalde S.V., Kobalava Zh.D., Solovyeva A.Е., Moiseev V.S. The concurrence of kidney and liver dysfunctions in decompensated heart failure. Therapeutic Archive. 2016;88(6):40–4. DOI: 10.17116/terarkh201688640-44

29. Yang JA, Kato TS, Shulman BP, Takayama H, Farr M, Jorde UP et al. Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: Use of the Model of End-stage Liver Disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system. The Journal of Heart and Lung Transplantation. 2012;31(6):601–10. DOI: 10.1016/j.healun.2012.02.027

30. Yamada T, Morita T, Furukawa Y, Tamaki S, Iwasaki Y, Kawasaki M et al. Prognostic value of the combination of cardiac power index and model of endstage liver disease excluding INR (MELD-XI) score in patients admitted for acute decompensated heart failure. Journal of the American College of Cardiology. 2018;71(11):A844. DOI: 10.1016/S0735-1097(18)31385-8

31. Kim MS, Kato TS, Farr M, Wu C, Givens RC, Collado E et al. Hepatic Dysfunction in Ambulatory Patients with Heart Failure: Application of the MELD scoring system for outcome prediction. Journal of the American College of Cardiology. 2013;61(22):2253–61. DOI: 10.1016/j.jacc.2012.12.056